| Cohort 1* - ELISA studies | Cohort 2** - proteomic studies |
---|
Characteristics | CIS → CIS | CIS → CDMS |
P values | CIS → CIS | CIS → CDMS |
P values |
---|
n | 27 | 29 | - | 18 | 18 | - |
Age (years)a
| 28.1 (9.6) | 27.4 (6.3) | 0.724 | 31.7 (7.3) | 30.2 (5.9) | 0.308 |
Female/male (% female) | 20/7 (74.1) | 20/9 (69.0) | 0.672 | 13/5 (72.2) | 13/5 (72.2) | 1 |
Follow-up time (years)a
| 8.2 (4.2) | 8.6 (3.3) | 0.819 | 6.1 (3.6) | 8.8 (2.7) | 0.098 |
Clinical presentation | | | | | | |
Optic neuritis | 15 (55.6) | 8 (27.6) | 0.206 | 9 (50.0) | 3 (16.7) | 0.152 |
Brainstem | 4 (14.8) | 7 (24.1) | | 2 (11.1) | 5 (27.8) | |
Spinal | 5 (18.5) | 8 (27.6) | | 3 (16.7) | 6 (33.3) | |
Others | 3 (11.1) | 6 (20.7) | | 4 (22.2) | 4 (22.2) | |
CSF cellsb
| 0.5 (0-5.0) | 2.0 (0-9.0) | 0.337 | 0 (2.4-3.5) | 4.0 (0-11.5) | 0.059 |
Proteins (mg/dL)b
| 33.0 (24.0-43.0) | 37.0 (26.8-57.3) | 0.391 | 32.5 (23.7-41.5) | 29.5 (24.0-51.8) | 0.705 |
- *Cohort 1 was used for the determination of CSF and serum levels of apolipoprotein AI, apolipoprotein AIV, vitronectin, and plasminogen by ELISA. **Cohort 2 was used for the quantification of CSF levels of semaphorin 7A and ala-beta-his-dipeptidase by selected reaction monitoring (SRM). A total of 23 (63.9%) patients were present in both cohorts of patients. aData are expressed as mean (standard deviation). bData are expressed as median (interquartile range). P values were obtained following comparisons between CIS → CIS patients and CIS → CDMS patients by means of the chi-square test (gender and clinical presentation) and the Mann-Whitney U test (remaining variables). Proteins (mg/dL) refers to protein concentration in mg/dL. CDMS, clinically definite multiple sclerosis; CIS, clinically isolated syndromes, CSF, cerebrospinal fluid.